Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 118 | 2024 | 5799 | 11.630 |
Why?
|
Carcinoma, Squamous Cell | 87 | 2024 | 4024 | 10.600 |
Why?
|
Carcinoma, Basal Cell | 20 | 2024 | 559 | 4.970 |
Why?
|
Mohs Surgery | 28 | 2024 | 221 | 4.830 |
Why?
|
Neoplasm Staging | 35 | 2024 | 11152 | 2.020 |
Why?
|
Neoplasm Recurrence, Local | 29 | 2024 | 9276 | 1.620 |
Why?
|
Neoplasm Invasiveness | 18 | 2024 | 3618 | 1.360 |
Why?
|
Keratosis, Actinic | 5 | 2021 | 72 | 1.240 |
Why?
|
Carcinoma, Merkel Cell | 6 | 2024 | 321 | 1.200 |
Why?
|
Organ Transplantation | 7 | 2024 | 1150 | 1.060 |
Why?
|
Lymphatic Metastasis | 11 | 2020 | 2943 | 0.890 |
Why?
|
Skin | 13 | 2022 | 4466 | 0.850 |
Why?
|
Nervous System Neoplasms | 2 | 2020 | 91 | 0.840 |
Why?
|
Head and Neck Neoplasms | 6 | 2024 | 2882 | 0.820 |
Why?
|
Penile Neoplasms | 1 | 2023 | 162 | 0.790 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2020 | 733 | 0.760 |
Why?
|
Chemoprevention | 2 | 2023 | 326 | 0.690 |
Why?
|
Keratoacanthoma | 1 | 2019 | 33 | 0.660 |
Why?
|
Retrospective Studies | 48 | 2024 | 80372 | 0.650 |
Why?
|
Bupivacaine | 1 | 2022 | 413 | 0.640 |
Why?
|
Lip Neoplasms | 1 | 2018 | 36 | 0.620 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2024 | 975 | 0.620 |
Why?
|
Humans | 142 | 2024 | 760621 | 0.610 |
Why?
|
Cohort Studies | 25 | 2024 | 41335 | 0.590 |
Why?
|
Peripheral Nerves | 2 | 2013 | 475 | 0.590 |
Why?
|
Fluorouracil | 3 | 2020 | 1631 | 0.580 |
Why?
|
Kidney Transplantation | 5 | 2024 | 4215 | 0.580 |
Why?
|
Death Certificates | 1 | 2018 | 167 | 0.570 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2021 | 1791 | 0.570 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1765 | 0.550 |
Why?
|
Nose Neoplasms | 2 | 2021 | 249 | 0.550 |
Why?
|
Prognosis | 23 | 2023 | 29658 | 0.550 |
Why?
|
Sunlight | 2 | 2023 | 337 | 0.550 |
Why?
|
Medicare | 5 | 2021 | 6786 | 0.530 |
Why?
|
Health Expenditures | 3 | 2020 | 2362 | 0.530 |
Why?
|
Aged | 51 | 2024 | 169152 | 0.500 |
Why?
|
Cause of Death | 2 | 2018 | 3725 | 0.500 |
Why?
|
Vulvar Neoplasms | 1 | 2018 | 263 | 0.500 |
Why?
|
Patient Selection | 2 | 2018 | 4283 | 0.490 |
Why?
|
Physician's Role | 2 | 2021 | 918 | 0.480 |
Why?
|
Melanoma | 8 | 2022 | 5697 | 0.480 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2015 | 64 | 0.470 |
Why?
|
Exanthema | 1 | 2019 | 504 | 0.470 |
Why?
|
Infection Control | 2 | 2012 | 983 | 0.460 |
Why?
|
Dermatofibrosarcoma | 1 | 2014 | 48 | 0.460 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 586 | 0.450 |
Why?
|
Female | 66 | 2024 | 391270 | 0.440 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1116 | 0.440 |
Why?
|
Male | 60 | 2024 | 359744 | 0.430 |
Why?
|
Surgical Wound Infection | 3 | 2012 | 1527 | 0.430 |
Why?
|
Sirolimus | 2 | 2018 | 1547 | 0.410 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1869 | 0.410 |
Why?
|
Aged, 80 and over | 28 | 2024 | 58995 | 0.400 |
Why?
|
Acetamides | 2 | 2023 | 256 | 0.390 |
Why?
|
Immunocompromised Host | 3 | 2021 | 857 | 0.390 |
Why?
|
Middle Aged | 42 | 2024 | 220352 | 0.380 |
Why?
|
Incidence | 13 | 2024 | 21392 | 0.380 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 624 | 0.370 |
Why?
|
Biopsy, Needle | 4 | 2019 | 1630 | 0.370 |
Why?
|
Sunburn | 1 | 2012 | 156 | 0.370 |
Why?
|
Keratinocytes | 5 | 2022 | 792 | 0.370 |
Why?
|
Medical Oncology | 4 | 2023 | 2313 | 0.370 |
Why?
|
Surgical Flaps | 3 | 2021 | 1669 | 0.360 |
Why?
|
Disease-Free Survival | 7 | 2023 | 6828 | 0.350 |
Why?
|
Health Care Costs | 3 | 2019 | 3258 | 0.340 |
Why?
|
Leg | 1 | 2015 | 1090 | 0.340 |
Why?
|
Pancreas Transplantation | 1 | 2010 | 196 | 0.340 |
Why?
|
Subcutaneous Fat | 1 | 2013 | 393 | 0.330 |
Why?
|
Patient Satisfaction | 2 | 2017 | 3448 | 0.290 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13630 | 0.290 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3202 | 0.280 |
Why?
|
Graft Rejection | 1 | 2020 | 4426 | 0.280 |
Why?
|
Risk Factors | 20 | 2024 | 74359 | 0.280 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 4166 | 0.280 |
Why?
|
Risk Assessment | 10 | 2022 | 24123 | 0.270 |
Why?
|
Academic Medical Centers | 4 | 2018 | 2754 | 0.270 |
Why?
|
Dermatology | 5 | 2020 | 914 | 0.260 |
Why?
|
Survival Analysis | 6 | 2020 | 10182 | 0.260 |
Why?
|
Health Behavior | 2 | 2021 | 2622 | 0.260 |
Why?
|
Skin Diseases, Vascular | 1 | 2005 | 41 | 0.250 |
Why?
|
United States | 22 | 2023 | 72461 | 0.250 |
Why?
|
Acitretin | 2 | 2023 | 16 | 0.240 |
Why?
|
Treatment Outcome | 17 | 2024 | 65017 | 0.240 |
Why?
|
Niacinamide | 2 | 2023 | 414 | 0.230 |
Why?
|
Disease Progression | 3 | 2020 | 13502 | 0.230 |
Why?
|
Aminoquinolines | 2 | 2018 | 108 | 0.230 |
Why?
|
Insurance Claim Review | 2 | 2019 | 738 | 0.230 |
Why?
|
Immunotherapy | 6 | 2024 | 4642 | 0.230 |
Why?
|
Facial Neoplasms | 2 | 2016 | 125 | 0.220 |
Why?
|
Laser Therapy | 3 | 2005 | 1089 | 0.220 |
Why?
|
Erythema | 1 | 2004 | 262 | 0.210 |
Why?
|
Skin Aging | 1 | 2004 | 141 | 0.210 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2018 | 640 | 0.210 |
Why?
|
Antibiotic Prophylaxis | 2 | 2010 | 643 | 0.210 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2023 | 27 | 0.210 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39261 | 0.210 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 1628 | 0.210 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4902 | 0.200 |
Why?
|
Eyelid Neoplasms | 1 | 2023 | 89 | 0.200 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 1056 | 0.200 |
Why?
|
Societies, Medical | 2 | 2018 | 3905 | 0.200 |
Why?
|
Adult | 24 | 2024 | 219994 | 0.200 |
Why?
|
Injections, Intralesional | 2 | 2020 | 278 | 0.200 |
Why?
|
Tranexamic Acid | 1 | 2024 | 176 | 0.190 |
Why?
|
Pamphlets | 1 | 2021 | 71 | 0.190 |
Why?
|
Keratolytic Agents | 1 | 2021 | 34 | 0.190 |
Why?
|
Antifibrinolytic Agents | 1 | 2024 | 292 | 0.180 |
Why?
|
Internship and Residency | 1 | 2021 | 5870 | 0.180 |
Why?
|
Tumor Burden | 2 | 2019 | 1895 | 0.180 |
Why?
|
Massachusetts | 3 | 2018 | 8803 | 0.180 |
Why?
|
Motor Activity | 1 | 2010 | 2687 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11712 | 0.180 |
Why?
|
Postoperative Hemorrhage | 1 | 2024 | 422 | 0.180 |
Why?
|
Frozen Sections | 1 | 2021 | 153 | 0.180 |
Why?
|
Administration, Cutaneous | 2 | 2020 | 713 | 0.170 |
Why?
|
Quality of Life | 3 | 2022 | 13308 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6544 | 0.170 |
Why?
|
Dioxygenases | 1 | 2021 | 335 | 0.160 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11071 | 0.160 |
Why?
|
Endocarditis, Bacterial | 1 | 2003 | 445 | 0.160 |
Why?
|
Methylprednisolone | 1 | 2020 | 384 | 0.160 |
Why?
|
Liver Transplantation | 1 | 2010 | 2325 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 191 | 0.160 |
Why?
|
Boston | 3 | 2019 | 9280 | 0.160 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 593 | 0.150 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 315 | 0.150 |
Why?
|
Skin Transplantation | 2 | 2021 | 1083 | 0.150 |
Why?
|
Sensitivity and Specificity | 5 | 2019 | 14660 | 0.150 |
Why?
|
Photochemotherapy | 3 | 2020 | 820 | 0.150 |
Why?
|
Carboplatin | 1 | 2020 | 788 | 0.140 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2803 | 0.140 |
Why?
|
Cryotherapy | 1 | 2017 | 161 | 0.140 |
Why?
|
False Negative Reactions | 1 | 2018 | 573 | 0.140 |
Why?
|
Preoperative Period | 1 | 2019 | 555 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2018 | 3486 | 0.140 |
Why?
|
Lip | 1 | 2018 | 197 | 0.140 |
Why?
|
Aftercare | 2 | 2019 | 916 | 0.130 |
Why?
|
Collagen | 1 | 2004 | 2636 | 0.130 |
Why?
|
Curettage | 1 | 2016 | 73 | 0.130 |
Why?
|
Survival Rate | 3 | 2020 | 12808 | 0.130 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7475 | 0.130 |
Why?
|
Biopsy | 3 | 2021 | 6771 | 0.130 |
Why?
|
Delphi Technique | 2 | 2021 | 829 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12159 | 0.130 |
Why?
|
Prednisone | 1 | 2020 | 1565 | 0.130 |
Why?
|
Anesthetics, Local | 1 | 2022 | 1001 | 0.130 |
Why?
|
Psoriasis | 1 | 2023 | 940 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 424 | 0.120 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 358 | 0.120 |
Why?
|
Medicare Part D | 1 | 2020 | 354 | 0.120 |
Why?
|
Epidermis | 1 | 2017 | 529 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 895 | 0.120 |
Why?
|
Observer Variation | 1 | 2021 | 2601 | 0.120 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4899 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1268 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1644 | 0.120 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2315 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1112 | 0.110 |
Why?
|
Hospitals | 3 | 2023 | 3928 | 0.110 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9585 | 0.110 |
Why?
|
Single-Blind Method | 2 | 2009 | 1578 | 0.110 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20080 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2852 | 0.110 |
Why?
|
Medicine | 1 | 2021 | 943 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12965 | 0.110 |
Why?
|
Transplantation, Homologous | 1 | 2022 | 4810 | 0.110 |
Why?
|
Sex Factors | 4 | 2024 | 10547 | 0.110 |
Why?
|
Scalp | 1 | 2016 | 389 | 0.110 |
Why?
|
Pyrazoles | 1 | 2023 | 1999 | 0.110 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2821 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10827 | 0.100 |
Why?
|
Databases, Factual | 2 | 2019 | 8035 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2020 | 630 | 0.100 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8552 | 0.100 |
Why?
|
Eccrine Porocarcinoma | 1 | 2012 | 18 | 0.100 |
Why?
|
Fibrosarcoma | 1 | 2014 | 308 | 0.100 |
Why?
|
Sex Distribution | 1 | 2017 | 2295 | 0.100 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1721 | 0.100 |
Why?
|
Esthetics | 1 | 2013 | 326 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
Disease Management | 2 | 2021 | 2514 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 867 | 0.100 |
Why?
|
Brachytherapy | 1 | 2019 | 1238 | 0.100 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2016 | 2895 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1786 | 0.090 |
Why?
|
Sweat Gland Neoplasms | 1 | 2012 | 117 | 0.090 |
Why?
|
Comorbidity | 3 | 2020 | 10551 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12531 | 0.090 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15289 | 0.090 |
Why?
|
Skin Pigmentation | 3 | 2020 | 277 | 0.090 |
Why?
|
Veterans | 2 | 2021 | 2642 | 0.090 |
Why?
|
Reoperation | 2 | 2020 | 4291 | 0.090 |
Why?
|
Suntan | 1 | 2009 | 17 | 0.090 |
Why?
|
E-Selectin | 1 | 2012 | 576 | 0.090 |
Why?
|
Prospective Studies | 6 | 2024 | 54303 | 0.090 |
Why?
|
Carcinoma | 1 | 2021 | 2331 | 0.090 |
Why?
|
Sterilization | 1 | 2010 | 130 | 0.090 |
Why?
|
Patient Care Team | 1 | 2021 | 2511 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2021 | 3663 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3529 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2421 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3696 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2014 | 6238 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2932 | 0.080 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3763 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2021 | 3242 | 0.070 |
Why?
|
Germany | 2 | 2020 | 873 | 0.070 |
Why?
|
Myeloid Cells | 1 | 2012 | 820 | 0.070 |
Why?
|
Ultraviolet Rays | 3 | 2020 | 1078 | 0.070 |
Why?
|
Pain | 1 | 2022 | 5066 | 0.070 |
Why?
|
Cross-Sectional Studies | 5 | 2023 | 25942 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5643 | 0.070 |
Why?
|
Age Factors | 3 | 2020 | 18416 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3758 | 0.070 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3763 | 0.070 |
Why?
|
Hospital Costs | 1 | 2012 | 976 | 0.070 |
Why?
|
Neoplasms | 2 | 2016 | 22072 | 0.070 |
Why?
|
Australia | 2 | 2020 | 1289 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9185 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8056 | 0.060 |
Why?
|
Fibrillar Collagens | 1 | 2004 | 42 | 0.060 |
Why?
|
Carcinoma in Situ | 2 | 2016 | 796 | 0.060 |
Why?
|
Attitude | 1 | 2009 | 777 | 0.060 |
Why?
|
Consensus | 1 | 2014 | 3113 | 0.060 |
Why?
|
Causality | 1 | 2010 | 1242 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2019 | 22053 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9411 | 0.060 |
Why?
|
Keratosis | 1 | 2004 | 80 | 0.060 |
Why?
|
Mass Screening | 1 | 2019 | 5423 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7806 | 0.060 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2004 | 95 | 0.060 |
Why?
|
Risk | 1 | 2015 | 9631 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2012 | 2141 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2010 | 2659 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 680 | 0.050 |
Why?
|
Psychometrics | 1 | 2012 | 3051 | 0.050 |
Why?
|
src-Family Kinases | 1 | 2004 | 535 | 0.050 |
Why?
|
Epidermal Growth Factor | 1 | 2004 | 695 | 0.050 |
Why?
|
Registries | 1 | 2018 | 8469 | 0.050 |
Why?
|
Private Practice | 1 | 2022 | 152 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3315 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2004 | 2558 | 0.050 |
Why?
|
5-Methylcytosine | 1 | 2021 | 146 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15840 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2009 | 3157 | 0.050 |
Why?
|
Transcription Factors | 2 | 2019 | 12103 | 0.040 |
Why?
|
Protective Clothing | 1 | 2021 | 103 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2013 | 899 | 0.040 |
Why?
|
Hutchinson's Melanotic Freckle | 1 | 2020 | 25 | 0.040 |
Why?
|
Sunscreening Agents | 1 | 2021 | 139 | 0.040 |
Why?
|
Population Surveillance | 1 | 2010 | 2608 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2020 | 118 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 3075 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 782 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2019 | 20509 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13981 | 0.040 |
Why?
|
Calcitriol | 1 | 2020 | 297 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10181 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3598 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17790 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3441 | 0.030 |
Why?
|
Histocytochemistry | 1 | 1997 | 700 | 0.030 |
Why?
|
Cell Division | 2 | 2009 | 4463 | 0.030 |
Why?
|
Tissue Expansion | 1 | 1997 | 160 | 0.030 |
Why?
|
Drug Synergism | 1 | 2020 | 1754 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2515 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36290 | 0.030 |
Why?
|
Cell Size | 1 | 1997 | 624 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 4550 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2234 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 1997 | 483 | 0.030 |
Why?
|
Young Adult | 2 | 2019 | 58741 | 0.030 |
Why?
|
Cryosurgery | 1 | 2020 | 475 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1677 | 0.030 |
Why?
|
Dinoprostone | 1 | 1997 | 598 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2020 | 448 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2435 | 0.030 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 491 | 0.030 |
Why?
|
Cyclic AMP | 1 | 1997 | 1456 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4490 | 0.030 |
Why?
|
Nitroarginine | 1 | 2012 | 66 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1405 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2013 | 18957 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 1997 | 1666 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2016 | 10446 | 0.030 |
Why?
|
Interleukin-15 | 1 | 2013 | 183 | 0.030 |
Why?
|
Arginase | 1 | 2012 | 80 | 0.020 |
Why?
|
Wound Closure Techniques | 1 | 2012 | 87 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2828 | 0.020 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 305 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 40165 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1185 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2023 | 2363 | 0.020 |
Why?
|
Receptors, CCR2 | 1 | 2012 | 215 | 0.020 |
Why?
|
Ultrasonography | 2 | 2018 | 5961 | 0.020 |
Why?
|
Dermis | 1 | 2012 | 202 | 0.020 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2012 | 514 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8515 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2012 | 630 | 0.020 |
Why?
|
Geography | 1 | 2012 | 661 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8482 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 1997 | 2651 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2013 | 0.020 |
Why?
|
Curriculum | 1 | 2023 | 3718 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 600 | 0.020 |
Why?
|
Signal Transduction | 3 | 2013 | 23376 | 0.020 |
Why?
|
Lectins, C-Type | 1 | 2013 | 587 | 0.020 |
Why?
|
Axilla | 1 | 2012 | 626 | 0.020 |
Why?
|
Body Weight | 1 | 2020 | 4611 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8555 | 0.020 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2009 | 133 | 0.020 |
Why?
|
Perforin | 1 | 2009 | 167 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2916 | 0.020 |
Why?
|
DNA | 2 | 2004 | 7233 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 3527 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 1837 | 0.020 |
Why?
|
History, 20th Century | 2 | 2009 | 2773 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2934 | 0.020 |
Why?
|
Granzymes | 1 | 2009 | 276 | 0.020 |
Why?
|
Mice, SCID | 1 | 2013 | 2627 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4373 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1110 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3616 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81208 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2013 | 1889 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2012 | 1303 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 1612 | 0.020 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2004 | 39 | 0.020 |
Why?
|
Patient Participation | 1 | 2014 | 1439 | 0.020 |
Why?
|
Ultraviolet Therapy | 1 | 2005 | 84 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 2379 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13314 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 2004 | 456 | 0.010 |
Why?
|
Intermediate Filament Proteins | 1 | 2004 | 263 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2009 | 1175 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2014 | 5201 | 0.010 |
Why?
|
Response Elements | 1 | 2004 | 308 | 0.010 |
Why?
|
Aminolevulinic Acid | 1 | 2004 | 142 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10344 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6360 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 478 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15687 | 0.010 |
Why?
|
Proteins | 1 | 1997 | 6029 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4000 | 0.010 |
Why?
|
Melanocytes | 1 | 2005 | 512 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3726 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 1959 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3707 | 0.010 |
Why?
|
Animals | 3 | 2021 | 167963 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 16939 | 0.010 |
Why?
|
Phenotype | 1 | 1997 | 16546 | 0.010 |
Why?
|
Preoperative Care | 1 | 2008 | 2256 | 0.010 |
Why?
|
Photosensitizing Agents | 1 | 2004 | 618 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2012 | 3539 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2004 | 3602 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2009 | 1469 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 5496 | 0.010 |
Why?
|
Cytokines | 1 | 2013 | 7343 | 0.010 |
Why?
|
Ligands | 1 | 2004 | 3276 | 0.010 |
Why?
|
DNA Replication | 1 | 2004 | 1412 | 0.010 |
Why?
|
Clinical Competence | 1 | 2012 | 4783 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6465 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 87810 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29932 | 0.010 |
Why?
|
Phosphorylation | 1 | 2004 | 8313 | 0.010 |
Why?
|
Apoptosis | 1 | 2009 | 9501 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 7593 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9467 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2004 | 11481 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11903 | 0.000 |
Why?
|